Credit Suisse Ag Novo Cure LTD Transaction History

Credit Suisse Ag

$101 Billion
Q1 2024

A detailed history of Credit Suisse Ag transactions in Novo Cure LTD stock. As of the latest transaction made, Credit Suisse Ag holds 847,520 shares of NVCR stock, worth $14.5 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares

847,520

Previous 853,516 0.7%

Holding current value

$14.5 Million

Previous $12.7 Million 3.96%

% of portfolio

0.01%

Previous 0.01%

28 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 10, 2024	SELL	$12.42 - $17.29 $74,470 - $103,670	-5,996 Reduced 0.7%	847,520 $13.2 Million
Q4 2023 Feb 08, 2024	BUY	$11.13 - $15.78 $317,839 - $450,629	28,557 Added 3.46%	853,516 $12.7 Million
Q3 2023 Nov 13, 2023	BUY	$16.15 - $42.35 $116,651 - $305,894	7,223 Added 0.88%	824,959 $13.3 Million
Q2 2023 Aug 11, 2023	SELL	$40.29 - $82.51 $2.42 Million - $4.95 Million	-59,952 Reduced 6.83%	817,736 $33.9 Million
Q1 2023 May 10, 2023	SELL	$56.44 - $118.81 $4.65 Million - $9.78 Million	-82,358 Reduced 8.58%	877,688 $52.8 Million

Q4 2022 Feb 13, 2023	SELL	$63.98 - $85.37 $7.62 Million - $10.2 Million	-119,050 Reduced 11.03%	960,046 $70.4 Million
Q3 2022 Nov 10, 2022	SELL	$67.99 - $89.57 $77,508 - $102,109	-1,140 Reduced 0.11%	1,079,096 $82 Million
Q2 2022 Aug 12, 2022	SELL	$56.6 - $89.9 $16 Million - $25.4 Million	-282,747 Reduced 20.74%	1,080,236 $75.1 Million
Q1 2022 May 16, 2022	BUY	$60.15 - $84.52 $99,849 - $140,303	1,660 Added 0.12%	1,362,983 $113 Million
Q4 2021 Feb 14, 2022	SELL	$75.08 - $121.99 $1.73 Million - $2.81 Million	-23,028 Reduced 1.66%	1,361,323 $102 Million
Q3 2021 Nov 12, 2021	BUY	$116.17 - $194.55 $13.3 Million - $22.3 Million	114,847 Added 9.05%	1,384,351 $161 Million
Q2 2021 Aug 16, 2021	SELL	$130.4 - $225.58 $47.4 Million - $82 Million	-363,347 Reduced 22.25%	1,269,504 $282 Million
Q1 2021 May 14, 2021	BUY	$124.11 - $190.17 $22.1 Million - $33.9 Million	178,392 Added 12.27%	1,632,851 $216 Million
Q4 2020 Feb 12, 2021	SELL	$112.16 - $174.14 $21.6 Million - $33.5 Million	-192,511 Reduced 11.69%	1,454,459 $252 Million
Q3 2020 Nov 13, 2020	SELL	$58.05 - $111.31 $32 Million - $61.3 Million	-550,890 Reduced 25.06%	1,646,970 $183 Million
Q2 2020 Aug 12, 2020	BUY	$57.2 - $74.41 $52.3 Million - $68 Million	913,568 Added 71.13%	2,197,860 $130 Million
Q1 2020 May 13, 2020	BUY	$57.05 - $95.75 $18.5 Million - $31 Million	323,594 Added 33.68%	1,284,292 $86.5 Million
Q4 2019 Feb 12, 2020	SELL	$68.3 - $93.8 $2.57 Million - $3.53 Million	-37,673 Reduced 3.77%	960,698 $81 Million
Q3 2019 Nov 12, 2019	SELL	$61.86 - $97.8 $11.6 Million - $18.3 Million	-187,216 Reduced 15.79%	998,371 $74.7 Million
Q2 2019 Aug 14, 2019	BUY	$42.22 - $63.23 $159,464 - $238,819	3,777 Added 0.32%	1,185,587 $75 Million
Q1 2019 May 14, 2019	SELL	$31.96 - $56.12 $9.77 Million - $17.2 Million	-305,761 Reduced 20.55%	1,181,810 $56.9 Million
Q4 2018 Feb 13, 2019	BUY	$28.72 - $52.63 $15.6 Million - $28.5 Million	541,917 Added 57.31%	1,487,571 $49.8 Million
Q3 2018 Nov 13, 2018	BUY	$32.0 - $52.4 $14.1 Million - $23.1 Million	440,543 Added 87.22%	945,654 $49.6 Million
Q2 2018 Aug 14, 2018	BUY	$19.85 - $32.0 $8.25 Million - $13.3 Million	415,809 Added 465.62%	505,111 $15.8 Million
Q1 2018 May 15, 2018	BUY	$19.3 - $23.65 $738,321 - $904,730	38,255 Added 74.94%	89,302 $1.95 Million
Q4 2017 Feb 14, 2018	SELL	$16.3 - $21.9 $255,323 - $343,041	-15,664 Reduced 23.48%	51,047 $1.03 Million
Q3 2017 Nov 14, 2017	BUY	$18.05 - $21.75 $541,806 - $652,869	30,017 Added 81.8%	66,711 $1.32 Million
Q2 2017 Aug 14, 2017	BUY	N/A	36,694	36,694 $635,000

Others Institutions Holding NVCR

# of Institutions

277

Shares Held

73.2M

Call Options Held

1.43M

Put Options Held

832K

View Full List

About NovoCure Ltd

Ticker NVCR
Exchange NASDAQ
Sector Healthcare
Industry Medical Instruments & Supplies
Shares Outstandng 104,950,000
Market Cap $1.8B
Description
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Europe, the Middle East, Africa, Japan, and Greater China. Its TTFields devices include Optune for the treatment of glioblastoma; and Optu...

More about NVCR

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

News

Stay updated on Credit Suisse Ag with notifications on news.

Account